An Analysis of Serum Interleukin-6 Levels to Predict Benefits of Medroxyprogesterone Acetate in Advanced or Recurrent Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|59|2|166-173

ISSN： 0030-2414

Source： Oncology, Vol.59, Iss.2, 2000-08, pp. : 166-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomized Controlled Comparative Study of Oral Medroxyprogesterone Acetate 1,200 and 600 mg in Patients with Advanced or Recurrent Breast Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 283-290

Karger

Access to resources Recommend Favorite

Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study

By  

Oncology, Vol. 56, Iss. 3, 1999-04 ,pp. : 198-201

Karger

Access to resources Recommend Favorite

Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer

By Yamac Deniz  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 801-809

Springer Publishing Company

Access to resources Recommend Favorite

Serum Levels of Interleukin 6 in Patients with Pustulosis Palmaris et Plantaris

By  

THE JOURNAL OF DERMATOLOGY, Vol. 20, Iss. 12, 1993-12 ,pp. : 763-766

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

By Robak T.   Gladalska A.   Stepien H.   Robak E.  

Mediators of Inflammation, Vol. 7, Iss. 5, 1998-10 ,pp. : 347-353

Informa Healthcare

Access to resources Recommend Favorite